You are here

Article Text

Article menu
Download PDFPDF
Meeting report
Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology
  1. S E Gabriel1,
  2. P Tugwell2,
  3. M Drummond3
  1. 1Department of Health Sciences Research and Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
  2. 2Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
  3. 3Centre for Health Economics, University of York, UK
  1. Correspondence to:
    Dr S E Gabriel, Department of Health Sciences Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA;
    gabriel.sherine{at}mayo.edu

Abstract

A working report from the OMERACT Health Economics Group. The group is working towards creating common standards for economic evaluation in rheumatology and also towards improving the scientific underpinning of economic evaluation, particularly pertaining to the rheumatic diseases. Preliminary recommendations for “reference cases” in osteoporosis, rheumatoid arthritis, and osteoarthritis are proposed.

  • OMERACT Economics Working Group
  • economic evaluation
  • rheumatology
  • NSAID, non-steroidal anti-inflammatory drug
  • OA, osteoarthritis
  • RA, rheumatoid arthritis

https://doi.org/10.1136/ard.61.4.370

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes